Halopyruvate Formulation for Stable Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as radiation and chemotherapy, often harm healthy cells while struggling to effectively target malignant cells, and existing formulations of 3-bromopyruvate are unstable, painful upon injection, and potentially toxic due to potassium phosphate buffer use.
Innovation Solution
A stable, non-irritating, and safe therapeutic cocktail with a high percentage of sugar molecules like sorbitol and inositol, combined with a sodium phosphate buffer, is developed to enhance the stability and delivery of 3-halopyruvate, minimizing solvolysis and toxicity, and ensuring effective targeting of cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 3-bromopyruvate is formulated in conventional aqueous buffers, then it provides therapeutic activity, but it suffers from instability due to solvolysis and potential toxicity
Solution Approach 1:
The patent changes the chemical parameters of the buffer formulation by replacing conventional aqueous phosphate buffers with a non-aqueous or reduced-aqueous system containing organic solvents like DMSO, ethanol, or isopropanol. This parameter change eliminates solvolysis reactions while maintaining the therapeutic activity of 3-bromopyruvate, thereby resolving the contradiction between stability and therapeutic effectiveness
Solution Approach 2:
The patent introduces organic solvents as intermediary substances that mediate between the active pharmaceutical ingredient (3-bromopyruvate) and the aqueous physiological environment. These intermediaries protect the halopyruvate from water-induced degradation while still allowing delivery to the target site, thus maintaining both stability and therapeutic activity
2Productivity
If high concentrations of halopyruvate are used to enhance cancer cell killing, then efficacy increases, but toxicity to healthy tissues increases
Solution Approach 1:
The patent employs targeted delivery mechanisms that concentrate the halopyruvate formulation specifically at the tumor site through localized injection or targeted carriers. This creates a local quality difference where high concentrations are present only where needed (cancer cells) while healthy tissues receive minimal exposure, thus resolving the contradiction between efficacy and toxicity
Solution Approach 2:
The patent segments the delivery system into targeted components that can distinguish between cancerous and healthy tissues. By using tumor-specific markers, targeted carriers, or localized administration routes, the treatment is segmented to affect only the malignant cells while sparing healthy tissues from toxic effects
3Productivity
If conventional chemotherapy is used to kill cancer cells, then cancer cell death is achieved, but healthy cells are also destroyed
Solution Approach 1:
The patent exploits the Warburg effect - the characteristic high glycolytic rate of cancer cells - and converts it into a selective vulnerability. By using glycolysis inhibitors that specifically target the elevated metabolic pathways of cancer cells, the treatment transforms the cancer cells' metabolic advantage into a selective weakness, allowing preferential killing of cancer cells while sparing healthy cells with normal metabolic rates
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific cytotoxicity to metabolic specificity. By targeting the altered metabolic parameters of cancer cells (elevated glycolysis, specific enzyme expressions), the treatment achieves selectivity based on metabolic phenotype rather than general cell division inhibition, thereby killing cancer cells while preserving healthy tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cocktail maintains 3-halopyruvate stability and reduces pain upon injection, eliminating potassium toxicity, allowing for the effective killing of cancer cells with minimal impact on healthy tissues, outperforming conventional anticancer agents in efficacy.
Implementation Method 1
Under aerobic conditions more than half the ATP produced in such tumor cells may be derived via glycolysis, in sharp contrast to normal cells, where this value is usually less than 10% with oxidative phosphorylation serving as the predominant method for ATP generation.
Data Source
AI summary
This invention provides compositions and methods for the treatment of cancer. An inhibitor cocktail buffer includes at least one sugar, a non-potassium containing buffer, and an inhibitor having general formula (I). Such an inhibitor cocktail buffer allows for the efficacious and safe delivery of various compounds, including halopyruvates and derivatives thereof, to human cancer patients.